Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
| Status: | Recruiting |
|---|---|
| Conditions: | Atrial Fibrillation, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 22 - Any |
| Updated: | 4/2/2016 |
| Start Date: | September 2010 |
| Contact: | Patti Naismith, RN |
| Email: | pnaismith@beaumonthospitals.com |
| Phone: | 248-898-8141 |
The objective of this study is to show that ranolazine is a safe, viable and potent
alternative for post-operative atrial fibrillation suppression in patients undergoing
cardiac surgery
alternative for post-operative atrial fibrillation suppression in patients undergoing
cardiac surgery
A single center, double blind, prospective, randomized study for patients who are scheduled
for elective cardiac surgery (CABG, or valve or CABG and valve). All patients who meet
criteria will be prospectively enrolled in a randomized fashion. Patients enrolled will be
assigned to receive twice daily identical capsules containing either placebo or ranolazine.
Study drug will be initiated 2 days before surgery. Patients will receive study drug
throughout their hospitalization and be kept on it for a full 2 weeks post operatively.
Patients will be seen in 2 weeks and receive a 30 day follow up contact visit.
for elective cardiac surgery (CABG, or valve or CABG and valve). All patients who meet
criteria will be prospectively enrolled in a randomized fashion. Patients enrolled will be
assigned to receive twice daily identical capsules containing either placebo or ranolazine.
Study drug will be initiated 2 days before surgery. Patients will receive study drug
throughout their hospitalization and be kept on it for a full 2 weeks post operatively.
Patients will be seen in 2 weeks and receive a 30 day follow up contact visit.
Inclusion Criteria:
- Indications for cardiac surgery (CABG, valve surgery or CABG and valve surgery, Able
to provide informed consent.
Exclusion Criteria:
- Documented atrial fibrillation within the previous 3 months
- Ongoing therapy with suppressive antiarrhythmic drugs
- Patient currently on digoxin
- Emergent surgery
- Patient receiving hemodialysis
- Concomitant use of ketoconazole, diltiazem, verapamil
- Known tolerance or hypersensitivity to ranolazine
- Pregnant individuals
- MAZE procedure performed during concurrent cardiac surgery
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials